Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

PURPOSE: Wee1 tyrosine kinase phosphorylates and inactivates cyclin-dependent kinase (Cdk) 1/2 in response to DNA damage. AZD1775 is a first-in-class inhibitor of Wee1 kinase with single-agent antitumor activity in preclinical models. We conducted a phase I study of single-agent AZD1775 in adult pat...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Do, Khanh, Wilsker, Deborah, Ji, Jiuping, Zlott, Jennifer, Freshwater, Tomoko, Kinders, Robert J., Collins, Jerry, Chen, Alice P., Doroshow, James H., Kummar, Shivaani
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2015
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4606059/
https://ncbi.nlm.nih.gov/pubmed/25964244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.60.4009
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller